The final invasive disease-free survival analysis displayed efficacy results at 90.7% by 36 months in ribociclib combined with NSAI while 87.6% was in the solo NSAI arm. Common adverse events (AEs) ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Opens in a new tab or window The FDA on Tuesday approved ribociclib ... overall survival data remain immature. "The FDA approval of Kisqali for this early breast cancer population, including ...

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

A recent study in Cancer ... survival in glioma-bearing mice. The report also discusses a case study in which a patient with progressive HGG received ribociclib, a CDK6 inhibitor approved for the ...

The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.

Set to start in 2025, Relay Therapeutics is moving toward a pivotal study of experimental treatment RLY-2608 in heavily ...

The study demonstrated clinically meaningful progression-free survival for heavily pretreated ... safety data for RLY-2608 in ...

Learn more about what your doctor may look for during a breast exam. Breast cancer survival rates vary widely based on many factors. Two of the most important factors are the type of cancer you ...